Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial

Zacks08-14

Accelerate Diagnostics, Inc. AXDX recently announced the completion of the pre-clinical trial of its WAVE system. The WAVE pre-clinical trial showed strong performance, along with strong instrument ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2459527104?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cJ7Tfg7ljIEMGiDFsviYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/afe95824683969079aeba27c8210bd37","is_english":true,"pubTime":"2024-08-14 22:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2459527104","market":"us","top_or_hot":-1,"title":"Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial","media":"Zacks","content":"<div>\n<p>Accelerate Diagnostics, Inc. AXDX recently announced the completion of the pre-clinical trial of its WAVE system. The WAVE pre-clinical trial showed strong performance, along with strong instrument ...</p>\n\n<a href=\"https://finance.yahoo.com/news/accelerate-diagnostics-axdx-completes-wave-140500904.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAccelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-14 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/accelerate-diagnostics-axdx-completes-wave-140500904.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Accelerate Diagnostics, Inc. AXDX recently announced the completion of the pre-clinical trial of its WAVE system. The WAVE pre-clinical trial showed strong performance, along with strong instrument ...</p>\n\n<a href=\"https://finance.yahoo.com/news/accelerate-diagnostics-axdx-completes-wave-140500904.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2023250504.SGD","symbol_name":"Allianz Thematica Cl AMg DIS H2-SGD","start_time":0,"source_url":"https://finance.yahoo.com/news/accelerate-diagnostics-axdx-completes-wave-140500904.html","article_id":"2459527104","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cJ7Tfg7ljIEMGiDFsviYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/afe95824683969079aeba27c8210bd37"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2459527104","pubTimestamp":1723644300,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Accelerate Diagnostics, Inc. AXDX recently announced the completion of the pre-clinical trial of its WAVE system. The WAVE pre-clinical trial showed strong performance, along with strong instrument reliability and assay reportability.With the latest success, the company is confident about WAVE product design and the system's capabilities. This, in turn, should help Accelerate Diagnostics to move ahead with a clinical trial and further commercialize the WAVE system.The WAVE system is designed to deliver rapid antimicrobial susceptibility testing  directly from positive blood culture  bottles and bacterial isolated colonies  to report accurate results within 4.5 hours, on average. The system, which will offer a comprehensive test menu, is incorporated with essential features to optimize workflow across laboratories.With the help of Accelerate Diagnostics’ WAVE system's rapid AST results, patients with serious infections can be put on targeted antimicrobial therapy to improve patient outc","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","BK4588":"碎股","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","BK4133":"新能源发电业者","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","IE00B19Z8X17.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH  \"AG\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","WAVE":"Eco Wave Power Global AB (publ)","BK4548":"巴美列捷福持仓","ISRG":"直觉外科公司","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","IE00B19Z8W00.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH \"A\" INC","BK4539":"次新股","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","AST":"Asterias Biotherapeutics, Inc.","AXDX":"Accelerate Diagnostics","AAQC":"Accelerate Acquisition Corp","DGX":"奎斯特诊疗","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4567":"ESG概念","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1917777945.USD":"安联专题基金Cl AT Acc","BK4534":"瑞士信贷持仓","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","TMDX":"TransMedics Group Inc.","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4196":"保健护理服务","LU0079474960.USD":"联博美国增长基金A","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","BK4082":"医疗保健设备","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H"},"translate_title":"Accelerate Diagnostics(AXDX)完成WAVE临床前试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AST":1,"WAVE":1,"TMDX":1,"ISRG":1,"AAQC":1,"AXDX":1,"DGX":0.9},"content_text":"Accelerate Diagnostics, Inc. AXDX recently announced the completion of the pre-clinical trial of its WAVE system. The WAVE pre-clinical trial showed strong performance, along with strong instrument reliability and assay reportability.\nWith the latest success, the company is confident about WAVE product design and the system's capabilities. This, in turn, should help Accelerate Diagnostics to move ahead with a clinical trial and further commercialize the WAVE system.\nAbout the WAVE System\nThe WAVE system is designed to deliver rapid antimicrobial susceptibility testing (AST) directly from positive blood culture (\"PBC\") bottles and bacterial isolated colonies (Isolates) to report accurate results within 4.5 hours, on average. The system, which will offer a comprehensive test menu, is incorporated with essential features to optimize workflow across laboratories. \nSignificance of the Pre-Clinical Trial\nWorld Health Organization estimated that Sepsis affects an estimated 49 million people globally each year, causing an estimated 11 million deaths, of which almost 1.3 million can be attributed to bacterial antimicrobial resistance. Additionally, Sepsis is the number one contributor to the U.S. healthcare system’s annual expenses, reaching approximately $62 billion.\nWith the help of Accelerate Diagnostics’ WAVE system's rapid AST results, patients with serious infections can be put on targeted antimicrobial therapy to improve patient outcomes, cut hospital costs and reduce antimicrobial resistance.\nMore on the News\nThe pre-clinical trial included 1,570 WAVE results compared with Broth Microdilution (\"BMD\"), the reference method. The trial included an equal number of prospective patient samples and site-selected challenge samples, which showed excellent concordance between sample types. Summary of the performance showed overall Essential Agreement (\"EA\") and Categorical Agreement (\"CA\") of approximately 95%.\nImage Source: Zacks Investment Research\nMarket Prospects\nPer a report from Skyquest, the global Antimicrobial Susceptibility Testing market size was valued at $3.79 billion in 2023 and is poised to reach $5.69 billion by 2031, at a CAGR of 5.2%. The primary factor influencing the market growth is the escalating burden of antimicrobial resistance, resulting in increased morbidity, mortality and healthcare costs. The rise in infectious disease outbreaks, hospital-acquired infections and the growing awareness about the need for targeted therapies also drive market growth.\nAccelerate Diagnostics’ recent development for its WAVE system is well-timed and in favour of the market growth.\nOther Recent Developments\nIn April 2024, Accelerate Diagnostics announced 510(k) submission to the FDA for its Accelerate Arc system and BC kit — an innovative, automated positive blood culture sample preparation platform for use with Bruker’s MALDI Biotyper CA (MBT-CA) System and MBT-CA Sepsityper software extension.\nPrice Performance\nYear to date, shares of AXDX have lost 55.3% against the industry’s 4.7 % growth.\nZacks Rank and Other Key Picks\nAccelerate Diagnostics currently carries a Zacks Rank #2 (Buy).\nOther other top-ranked stocks in the broader medical space are Intuitive Surgical ISRG, TransMedics Group TMDX and Quest Diagnostics DGX. While Intuitive Surgical and TransMedics sport a Zacks Rank #1 (Strong Buy) each, Quest Diagnostics carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIntuitive Surgical’s shares have surged 53% in the past year. Estimates for the company’s earnings have moved north 5.1% to $1.65 per share for 2024 in the past 30 days.\nISRG’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.\nEstimates for TransMedics’ 2024 EPS have moved up 83.3% to 22 cents in the past 30 days. Shares of the company have soared 157.1% in the past year compared with the industry’s 7.2% growth.\nTMDX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.\nEstimates for Quest Diagnostics’ 2024 EPS have decreased 0.4% to $2.28 in the past 30 days. In the past year, shares of HAE have risen 13% compared with the industry’s 18.4% growth.\nIn the last reported quarter, DGX delivered an earnings surprise of 1.73%. The company has a trailing four-quarter average earnings surprise of 3.31%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nQuest Diagnostics Incorporated (DGX) : Free Stock Analysis Report\nIntuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report\nAccelerate Diagnostics, Inc. (AXDX) : Free Stock Analysis Report\nTransMedics Group, Inc. (TMDX) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459527104"}